<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609245</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 070849</org_study_id>
    <nct_id>NCT00609245</nct_id>
  </id_info>
  <brief_title>Effect of Valproic Acid Concentration on Photic Response</brief_title>
  <official_title>Effect of Small Changes in Plasma Valproic Acid Concentration on the Photoparoxysmal Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to learn if small changes in the amount of a valproate in the blood (given&#xD;
      through an IV) will change the way the brain reacts to flashing lights.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Photosensitive epilepsy is a form of epilepsy that is considered to have a genetic basis in&#xD;
      most instances. It is a reflex type of epilepsy. Patients with this condition exhibit&#xD;
      epileptic activity patterns (called photoparoxysmal response-PPR) on their EEG during&#xD;
      intermittent photic stimulation with certain flash frequencies.&#xD;
&#xD;
      Specific Aims&#xD;
&#xD;
        1. To determine the extent of the pharmacodynamic effect of small changes in total and free&#xD;
           VPA concentration via constant infusion of intravenous sodium valproate within the same&#xD;
           photosensitive epilepsy patient.&#xD;
&#xD;
        2. To determine the change in total and free VPA concentration required to achieve maximal&#xD;
           effect on PPR in patients with photosensitive epilepsy.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
        1. Valproic acid (VPA) demonstrates differential pharmacodynamic effect on PPR with small&#xD;
           changes in VPA concentration (5-20 mg/L changes in total, or 0.5 to 2 mg/L changes in&#xD;
           free VPA) within the same patient. In essence, the VPA concentration-response curve in&#xD;
           patients with photosensitive epilepsy is relatively steep.&#xD;
&#xD;
        2. Intravenously-administered VPA will demonstrate a reduction in standard photosensitive&#xD;
           range (SPR) or abolition of PPR for at least 80% of patients studied, when the entire&#xD;
           range of free VPA concentrations is considered.&#xD;
&#xD;
      Photosensitivity, defined as a PPR on intermittent photic stimulation (IPS), is found in&#xD;
      approximately 5% of all epileptic patients. Markedly photosensitive patients are usually&#xD;
      sensitive to IPS within clearly defined limits of flash frequency (mostly between 10-30 Hz).&#xD;
      This photosensitivity range, the difference between the highest and lowest flash rates that&#xD;
      consistently elicit a photoparoxysmal response (PPR), can be used as a quantitative measure&#xD;
      of photosensitivity.&#xD;
&#xD;
      Administration of some antiepileptic drugs (AEDS) can diminish or even abolish PPR. With a&#xD;
      standard set of tested frequencies, a standard photosensitive range (SPR) can be used to&#xD;
      measure drug effect on photosensitivity. Combined with blood level monitoring, the model&#xD;
      offers information about actual pharmacodynamic effect as measured with IPS related to the&#xD;
      changes in blood levels.&#xD;
&#xD;
      The standardized IPS procedure includes delivery of short (5 second-) trains of flashes. The&#xD;
      stimulation starts with the lowest frequencies (which usually do not produce a PPR) only up&#xD;
      to the limits of the photosensitivity range (the threshold frequencies for which the patient&#xD;
      shows an epileptiform EEG response). After that the stimulation starts again with the highest&#xD;
      frequencies (which also do not produce a PPR) down to the frequency that produces a definite&#xD;
      PPR.&#xD;
&#xD;
      The photic stimulator will be manually controlled for all stimulations in order to abort the&#xD;
      stimulation when a clear PPR is elicited. With all stimulations, there is simultaneous&#xD;
      recording of the EEG and direct observation of the patient for clinical changes. With all the&#xD;
      safety measures in place, the likelihood of provoking prominent clinical seizures is&#xD;
      extremely low.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in SPR During Placebo and VPA Infusions</measure>
    <time_frame>At the start of EEG monitoring/drug infusion, and on an hourly basisfor 12 hours</time_frame>
    <description>standard photosensitive range (SPR) Each participant is exposed to intermittent photic stimulation at 14 predetermined frequencies in order to detect changes in response around typical upper and lower frequency thresholds (e.g., 2 Hz, 5 Hz, 8Hz, 10 Hz, etc.). Each flash frequency that elicits a photosensitive response is considered one &quot;step&quot;, and the result is transformed into a metric called the standardized photosensitive range (SPR). The SPR ranges from 0 to 14, where each point represents the number of flash frequencies that elicited a photosensitive response.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Photosensitive Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo then Valproic Acid (VPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients will have placebo on day 1 and VPA infusion on day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).</description>
    <arm_group_label>Placebo then Valproic Acid (VPA)</arm_group_label>
    <other_name>Depacon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.</description>
    <arm_group_label>Placebo then Valproic Acid (VPA)</arm_group_label>
    <other_name>Normal Saline (NS) and 5% Dextrose in water (D5W)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients&#xD;
&#xD;
          -  Aged 15 to 65 years&#xD;
&#xD;
          -  Patients with a diagnosis of epilepsy for which they are either taking up two AEDs,&#xD;
             not including VPA/divalproex, or no AEDs&#xD;
&#xD;
          -  Patients with a reproducible IPS-induced photo-paroxysmal responses of at least 7&#xD;
             SPR-EEG units as measured at two different time points in the day (pm screening Study&#xD;
             Visit 1 and am of Visit 2).&#xD;
&#xD;
          -  Are in good health (with the exception of epilepsy).&#xD;
&#xD;
          -  Able and willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not exhibiting a photo-paroxysmal-EEG response&#xD;
&#xD;
          -  Patients with active psychogenic seizures&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Women of reproductive potential who do not agree to use effective birth-control&#xD;
             methods during the study and for one week after receiving study drug.&#xD;
&#xD;
          -  Patients taking any dosage form of VPA/divalproex within 4 weeks prior to the study&#xD;
&#xD;
          -  Patients taking more than two concomitant AEDs&#xD;
&#xD;
          -  Patients with any clinically significant laboratory abnormality, which in the opinion&#xD;
             of the investigator, will exclude the patient from the study&#xD;
&#xD;
          -  Patients who are suffering from active liver disease indicated by abnormal liver&#xD;
             function tests greater than three times the upper limit of normal (AST and ALT),&#xD;
             patients with porphyria, or patients with a family history of severe hepatic&#xD;
             dysfunction&#xD;
&#xD;
          -  Patients with a history of alcoholism, drug abuse, or drug addiction (within the past&#xD;
             12 months)&#xD;
&#xD;
          -  Patients with a history of sensitivity or allergic reaction to valproate / divalproex&#xD;
&#xD;
          -  Patients who have a medical history which would contraindicate sodium valproate (VPA)&#xD;
             administration&#xD;
&#xD;
          -  Patients who have participated in any other trials involving an investigational&#xD;
             product or device within 30 days of screening.&#xD;
&#xD;
          -  Patients with clinically significant ECG abnormalities, as judged by the PI, at&#xD;
             screening visit&#xD;
&#xD;
          -  Patients with such poor intravenous access that the insertion of two intravenous&#xD;
             catheters (one for sodium valproate infusion and one, in a contralateral arm vein, for&#xD;
             serial blood sampling) for a 12-hour period is not possible.&#xD;
&#xD;
          -  Patients who received benzodiazepines within one week of study initiation&#xD;
&#xD;
          -  Status epilepticus within one year of screening&#xD;
&#xD;
          -  Generalized tonic-clonic seizure within 24 hours of photic stimulation procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bassel Abou-Khalil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Rosenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Comprehensive Epilepsy Care Center for Children &amp; Adults</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorothee Kasteleijn-Nolst Trenite, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Comprehensive Epilepsy Care Center for Children &amp; Adults</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Comprehensive Epilepsy Care Center for Children &amp; Adults</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Bassel Abou-Khalil</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>photosensitive</keyword>
  <keyword>valproic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Reflex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valproate Infusion</title>
          <description>placebo: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.&#xD;
Valproic Acid: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous Na VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valproate Infusion</title>
          <description>placebo: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.&#xD;
Valproic Acid: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous Na VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>presence of photoparoxysmal response</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in SPR During Placebo and VPA Infusions</title>
        <description>standard photosensitive range (SPR) Each participant is exposed to intermittent photic stimulation at 14 predetermined frequencies in order to detect changes in response around typical upper and lower frequency thresholds (e.g., 2 Hz, 5 Hz, 8Hz, 10 Hz, etc.). Each flash frequency that elicits a photosensitive response is considered one &quot;step&quot;, and the result is transformed into a metric called the standardized photosensitive range (SPR). The SPR ranges from 0 to 14, where each point represents the number of flash frequencies that elicited a photosensitive response.</description>
        <time_frame>At the start of EEG monitoring/drug infusion, and on an hourly basisfor 12 hours</time_frame>
        <population>1 patient did not complete infusion of Valproic Acid due to Adverse Event. This patient was not included in final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>The investigators will utilize intravenous sodium valproate. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous Na VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in SPR During Placebo and VPA Infusions</title>
          <description>standard photosensitive range (SPR) Each participant is exposed to intermittent photic stimulation at 14 predetermined frequencies in order to detect changes in response around typical upper and lower frequency thresholds (e.g., 2 Hz, 5 Hz, 8Hz, 10 Hz, etc.). Each flash frequency that elicits a photosensitive response is considered one &quot;step&quot;, and the result is transformed into a metric called the standardized photosensitive range (SPR). The SPR ranges from 0 to 14, where each point represents the number of flash frequencies that elicited a photosensitive response.</description>
          <population>1 patient did not complete infusion of Valproic Acid due to Adverse Event. This patient was not included in final analysis.</population>
          <units>standard photosensitive range (SPR)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.917" lower_limit="14.739" upper_limit="17.431"/>
                    <measurement group_id="O2" value="14.609" lower_limit="12.903" upper_limit="17.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valproic Acid</title>
          <description>Valproic Acid: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous Na VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bassel Abou-Khalil, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-936-0060</phone>
      <email>bassel.abou-khalil@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

